NLRP12
NLRP12 (NLR family pyrin domain containing 12, also known as PYPAF7, Monarch1, RNO2, PAN6, CLR19.3 and NALP12) is a cytoplasmic member of the NLRP family. It acts as an attenuating factor of inflammation, suppressing inflammatory signalling in myeloid cells. Browse Assay Genie's current range of NLRP12 research reagents below, or read on for the biology behind the target.
NLRP12 is an essential mitigator of inflammation. It is primarily expressed in dendritic cells and macrophages, where it inhibits both canonical and non-canonical NF-kappa-B activation as well as ERK activation. It also acts as a negative regulator of NOD2, targeting it for degradation via the proteasome pathway, and in turn promotes bacterial tolerance.
The NLRP12 protein also restrains antiviral signalling. It inhibits RIGI-mediated immune responses against RNA viruses by reducing TRIM25-mediated 'Lys-63'-linked RIGI activation, while enhancing RNF125-mediated 'Lys-48'-linked RIGI degradation. In adipose tissue it acts as a negative regulator of the inflammatory response, helping to mitigate obesity and obesity-associated diseases.
The NLRP12 gene encodes a member of the CATERPILLER family of cytoplasmic proteins, which belongs to the NLRP family. The protein contains an N-terminal pyrin domain, a NACHT domain, a NACHT-associated domain and a C-terminal leucine-rich repeat region. HGNC lists it in the NLR family and the pyrin domain containing group, and its previous name was NACHT, leucine rich repeat and PYD containing 12. It suppresses inflammatory responses in activated monocytes, and mutations in the gene cause familial cold autoinflammatory syndrome type 2. Alternative splicing results in multiple transcript variants. A mouse ortholog, Nlrp12, is recorded.
NLRP12 is expressed mainly in dendritic cells and macrophages, making it a useful focus for studying how innate immune cells limit their own activation.
NLRP12 inhibits canonical and non-canonical NF-kappa-B and ERK activation, so it is studied as a brake on inflammatory signalling.
Mutations in NLRP12 cause familial cold autoinflammatory syndrome type 2, linking the protein to the study of inherited periodic inflammatory disorders.
NLRP12 regulates NOD2 and RIGI, connecting it to research on bacterial tolerance and control of RNA virus immune signalling.
NLRP12 is a potent mitigator of inflammation. It inhibits canonical and non-canonical NF-kappa-B and ERK activation, targets NOD2 for proteasomal degradation, and dampens RIGI-mediated antiviral signalling. It also limits inflammatory responses in adipose tissue, which is relevant to obesity.
NLRP12 is also known as RNO2, PYPAF7, Monarch1, PAN6, CLR19.3 and NALP12. The UniProt protein name is NACHT, LRR and PYD domains-containing protein 12, and the earlier HGNC name was NACHT, leucine rich repeat and PYD containing 12.
Yes. According to the NCBI Gene summary, mutations in the NLRP12 gene cause familial cold autoinflammatory syndrome type 2. The protein also acts as a negative regulator of inflammation in adipose tissue, and a mouse ortholog, Nlrp12, exists; check the datasheet of any product for its validated reactivity.
Other NLRP family members and NLRP12 pathway partners involved in inflammation and innate immune signalling.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P59046; product specifications from Assay Genie datasheets.